More than a 100-year experience with drug development and discovery
More than 700 scientists and specialists work within research and development in LEO Pharma to develop new treatments. Together, we take the drugs all the way - from research to registration.
We work relentlessly to help patients with skin diseases. We are driven by our desire to offer new, innovative medicines better and faster than anyone else, and our aspiration is to help 125 million patients by 2025.
Executive Vice President
LEO Pharma Group completes divestment of Emollients and Proctology Portfolio to Karo Pharma
Ballerup, DENMARK, March 2, 2020 – LEO Pharma today announced that the divestment of its emollients and proctology portfolio to Karo Pharma for 90 M EUR has been completed.
LEO Pharma Enters License Agreement with Oneness Biotech and Microbio Shanghai for FB825
BALLERUP, Denmark, April 15, 2020 – LEO Pharma A/S, a global leader in medical dermatology, today announced that is has signed a worldwide exclusive licensing agreement with Oneness Biotech (Taiwan, TPEx: 4743) and Microbio Shanghai (China) covering the development and commercialization of the novel Atopic Dermatitis (AD) and Allergic Asthma drug candidate, FB825.